Quadruple Immunotherapy for Neuroblastoma
Condition: Neuroblastoma Recurrent Interventions: Biological: Natural killer cell; Drug: Dinutuximab beta; Drug: Interleukin-2; Drug: Granulocyte-Macrophage Colony-Stimulating Factor; Drug: Spironolactone Sponsors: Hong Kong Children's Hospital; The University of Hong Kong Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2023 Category: Research Source Type: clinical trials
Effects of half-dose spiomet treatment in girls with early puberty and accelerated bone maturation: a multicenter, randomized, placebo-controlled study protocol
DiscussionThe present study, if successful, may provide a first proof of the concept that the rapid maturation of girls with an upward mismatch between pre- and post-natal weight gain can be slowed down with a fixed low-dose combination of old and safe generics jointly targeting a reduction of ectopic fat without necessarily lowering body weight.Trial registrationEudraCT 2021-006766-21. Registered on May 30, 2022. (Source: Trials)
Source: Trials - January 24, 2023 Category: Research Source Type: clinical trials